Arsanis Biosciences GmbH, an early stage biotechnology company developing anti-infective human monoclonal antibodies, today announced the award of a grant for the development of monoclonal antibody therapeutics against nosocomial infections from the Austrian Research Promotion Agency (Forschungs-Förderungs-Gesellschaft or “FFG”), the leading public funding agency for translational research in Austria. The support from FFG for the first year is EUR 1.19 million; additional funding (up to 70% of the total budget of EUR 12.5 million for the program) is expected in the following three years.

View Document